Scientists Turn One Stem Cell Into 14 Million Cancer-Fighting NK Cells
Chinese researchers developed a breakthrough method to mass-produce powerful immune cells that hunt and destroy cancer tumors.
20 articles
Chinese researchers developed a breakthrough method to mass-produce powerful immune cells that hunt and destroy cancer tumors.
A first-in-human trial shows CAR-modified stem cell memory T cells outperform standard CAR T cells in expansion, persistence, and complete responses.
STAR-FACS technique enables researchers to isolate and study rare cancer cells with specific mutations, revealing how genetic changes drive tumor behavior.
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
Leukemic stem cells produce their own ketone bodies to block ferroptosis, revealing a metabolic weak point that could be targeted therapeutically.
Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
Scientists modified patients' immune cells to better recognize and attack cancer tumors expressing NY-ESO-1 protein.
Researchers identify four LSC subtypes that predict venetoclax resistance and reveal matched subtype-specific therapies for AML patients.
A novel immune-evasion mechanism in triple-negative breast cancer reveals how cancer stem cells suppress anti-tumor immunity via extracellular vesicles.
Small trial tests innovative immune cell therapy for patients with relapsed non-Hodgkin's lymphoma who failed standard treatments.
Scientists identify a mitochondria-proteasome-haem pathway that silences immune cells โ and show bortezomib can fix it in CAR-T therapy.
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
Genetically modified immune cells target blood cancer that stopped responding to standard treatments in 28-patient trial.
Researchers explored whether cancer-derived cell-free DNA and telomere maintenance mutations could serve as early warning biomarkers in soft tissue sarcoma patients.
Scientists used precise gene editing to enhance CAR-T cell therapy, creating more effective and persistent cancer treatments.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
Revolutionary CRISPR technique bypasses lab manufacturing by programming immune cells to fight cancer directly in the body.